The weekly litigation news digest is live. Subscribe now

Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains

Patent No. EP2637670 (titled "Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains") was filed by Amgen on Oct 27, 2011. The application was issued on Mar 13, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
LINDIS BIOTECHDec 7, 2017GRAF VON STOSCH
F HOFFMANN LA ROCHEDec 1, 2017MEWBURN ELLIS

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2637670

AMGEN
Application Number
EP11788077A
Filing Date
Oct 27, 2011
Status
Patent Maintained As Amended
Feb 9, 2024
Publication Date
Mar 13, 2024